{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:16:02Z","timestamp":1789013762517,"version":"build-2803163510"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:00:00Z","timestamp":1608163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AR 69572"],"award-info":[{"award-number":["AR 69572"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We evaluated which aPL combinations increase the risk of future thrombosis in patients with SLE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective cohort study consisted of SLE patients who had been tested for all seven aPL (LA, aCL isotypes IgM, IgG and IgA, and anti-\u03b22-glycoprotein I isotypes IgM, IgG and IgA). Pooled logistic regression was used to assess the relationship between aPL and thrombosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 821 SLE patients with a total of 75\u00a0048 person-months of follow-up. During the follow-up we observed 88 incident cases of thrombosis: 48 patients with arterial, 37 with venous and 3 with both arterial and venous thrombosis. In individual models, LA was the most predictive of any [age-adjusted rate ratio 3.56 (95% CI 2.01, 6.30), P\u2009&amp;lt;\u20090.0001], venous [4.89 (2.25, 10.64), P\u2009&amp;lt;\u20090.0001] and arterial [3.14 (1.41, 6.97), P\u2009=\u20090.005] thrombosis. Anti-\u03b22-glycoprotein I IgA positivity was a significant risk factor for any [2.00 (1.22, 3.3), P\u2009=\u20090.0065] and venous [2.8 (1.42, 5.51), P\u2009=\u20090.0029] thrombosis. Only anti-\u03b22-glycoprotein I IgA appeared to add significant risk to any [1.73 (1.04, 2.88), P\u2009=\u20090.0362] and venous [2.27 (1.13, 4.59), P\u2009=\u20090.0218] thrombosis among those with LA. We created an interaction model with four categories based on combinations of LA and other aPL to look at the relationships between combinations and the risk of thrombosis. In this model LA remained the best predictor of thrombosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study demonstrated that in SLE, LA remained the best predictor of thrombosis and adding additional aPL did not add to the risk, with the exception of anti-\u03b22-glycoprotein I IgA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa857","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T23:29:33Z","timestamp":1607038173000},"page":"3770-3777","source":"Crossref","is-referenced-by-count":35,"title":["Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus"],"prefix":"10.1093","volume":"60","author":[{"given":"Selcan","family":"Demir","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA"},{"name":"Department of Pediatric Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence S","family":"Magder","sequence":"additional","affiliation":[{"name":"Division of Biostatistics and Bioinformatics, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Petri","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,17]]},"reference":[{"key":"2021080220002683300_keaa857-B1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"2021080220002683300_keaa857-B2","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1136\/bmj.287.6398.1021","article-title":"Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant","volume":"287","author":"Boey","year":"1983","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2021080220002683300_keaa857-B3","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(83)91267-9","article-title":"Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus","volume":"2","author":"Harris","year":"1983","journal-title":"Lancet"},{"key":"2021080220002683300_keaa857-B4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1006\/jaut.2000.0409","article-title":"Epidemiology of the antiphospholipid antibody syndrome","volume":"15","author":"Petri","year":"2000","journal-title":"J Autoimmun"},{"key":"2021080220002683300_keaa857-B5","doi-asserted-by":"crossref","first-page":"e1\u20132","DOI":"10.1016\/j.semarthrit.2014.09.013","article-title":"A 2014 update on the management of patients with systemic lupus erythematosus","volume":"44","author":"Merrill","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"2021080220002683300_keaa857-B6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.5152\/eurjrheum.2015.0085","article-title":"The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus","volume":"3","author":"Unlu","year":"2016","journal-title":"Eur J Rheumatol"},{"key":"2021080220002683300_keaa857-B7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/01.md.0000091181.93122.55","article-title":"Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients","volume":"82","author":"Cervera","year":"2003","journal-title":"Medicine (Baltimore"},{"key":"2021080220002683300_keaa857-B8","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1177\/096120339800700214","article-title":"The catastrophic antiphospholipid syndrome, 1998. A review of the clinical features, possible pathogenesis and treatment","volume":"7","author":"Asherson","year":"1998","journal-title":"Lupus"},{"key":"2021080220002683300_keaa857-B9","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","article-title":"Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature","volume":"101","author":"Galli","year":"2003","journal-title":"Blood"},{"key":"2021080220002683300_keaa857-B10","doi-asserted-by":"crossref","first-page":"e000107","DOI":"10.1136\/lupus-2015-000107","article-title":"Assessment of the independent associations of IgG, IgM and IgA isotypes of anticardiolipin with thrombosis in SLE","volume":"3","author":"Domingues","year":"2016","journal-title":"Lupus Sci Med"},{"key":"2021080220002683300_keaa857-B11","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3899\/jrheum.100650","article-title":"IgM anti-\u03b22 glycoprotein I is protective against lupus nephritis and renal damage in systemic lupus erythematosus","volume":"38","author":"Mehrani","year":"2011","journal-title":"J Rheumatol"},{"key":"2021080220002683300_keaa857-B12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1538-7836.2008.02862.x","article-title":"Invitation to a debate on the serological criteria that define the antiphospholipid syndrome","volume":"6","author":"Galli","year":"2008","journal-title":"J Thromb Haemost"},{"key":"2021080220002683300_keaa857-B13","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1111\/j.1538-7836.2007.02669.x","article-title":"Revised classification criteria for antiphospholipid syndrome and the thrombotic risk in patients with autoimmune diseases","volume":"5","author":"Swad\u017aba","year":"2007","journal-title":"J Thromb Haemost"},{"key":"2021080220002683300_keaa857-B14","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1055\/s-0038-1649940","article-title":"Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome","volume":"74","author":"Pierangeli","year":"1995","journal-title":"Thromb Haemost"},{"key":"2021080220002683300_keaa857-B15","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1177\/0961203308093460","article-title":"IgA antiphospholipid antibodies are an independent risk factor for thromboses","volume":"17","author":"Shen","year":"2008","journal-title":"Lupus"},{"key":"2021080220002683300_keaa857-B16","first-page":"74","article-title":"IgA class anti-beta2-glycoprotein I in patients with systemic lupus erythematosus","volume":"25","author":"Tsutsumi","year":"1998","journal-title":"J Rheumatol"},{"key":"2021080220002683300_keaa857-B17","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1002\/art.38131","article-title":"Value of isolated IgA anti-beta2-glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome","volume":"65","author":"Murthy","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2021080220002683300_keaa857-B18","doi-asserted-by":"crossref","first-page":"e0178889","DOI":"10.1371\/journal.pone.0178889","article-title":"Incidence of thromboembolic events in asymptomatic carriers of IgA anti \u03b22 glycoprotein-I antibodies","volume":"12","author":"Tortosa","year":"2017","journal-title":"PLoS One"},{"key":"2021080220002683300_keaa857-B19","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3899\/jrheum.100568","article-title":"Association of IgA Anti-beta2 glycoprotein I with clinical and laboratory manifestations of systemic lupus erythematosus","volume":"38","author":"Mehrani","year":"2011","journal-title":"J Rheumatol"},{"key":"2021080220002683300_keaa857-B20","doi-asserted-by":"crossref","first-page":"704395","DOI":"10.1155\/2014\/704395","article-title":"Isolated IgA anti-\u03b22 glycoprotein I antibodies in patients with clinical criteria for antiphospholipid syndrome","volume":"2014","author":"Ruiz-Garc\u00eda","year":"2014","journal-title":"J Immunol Res"},{"key":"2021080220002683300_keaa857-B21","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F","article-title":"International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop","volume":"42","author":"Wilson","year":"1999","journal-title":"Arthritis Rheum"},{"key":"2021080220002683300_keaa857-B22","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2020-000406","article-title":"Evaluation of different ways to identify persistent positivity of lupus anticoagulant in systemic lupus erythematosus","volume":"7","author":"Petri","year":"2020","journal-title":"Lupus Sci Med"},{"key":"2021080220002683300_keaa857-B23","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2021080220002683300_keaa857-B24","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum"},{"key":"2021080220002683300_keaa857-B25","first-page":"1823","article-title":"The automated modified Russell viper venom time test for the lupus anticoagulant","volume":"18","author":"Petri","year":"1991","journal-title":"J Rheumatol"},{"key":"2021080220002683300_keaa857-B26","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12874-016-0248-6","article-title":"A comparison of time dependent Cox regression, pooled logistic regression and cross sectional pooling with simulations and an application to the Framingham Heart Study","volume":"16","author":"Ngwa","year":"2016","journal-title":"BMC Med Res Methodol"},{"key":"2021080220002683300_keaa857-B27","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.autrev.2013.11.004","article-title":"Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis","volume":"13","author":"Reynaud","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2021080220002683300_keaa857-B28","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1474-4422(09)70239-X","article-title":"Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study","volume":"8","author":"Urbanus","year":"2009","journal-title":"Lancet Neurol"},{"key":"2021080220002683300_keaa857-B29","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1182\/blood-2014-11-611129","article-title":"Increased mortality in patients with the lupus anticoagulant: the Vienna Lupus Anticoagulant and Thrombosis Study (LATS)","volume":"125","author":"Gebhart","year":"2015","journal-title":"Blood"},{"key":"2021080220002683300_keaa857-B30","doi-asserted-by":"crossref","first-page":"e309\u201310","DOI":"10.1161\/ATVBAHA.107.153536","article-title":"A comparison of lupus anticoagulant-positive patients with clinical picture of antiphospholipid syndrome and those without","volume":"27","author":"Pengo","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2021080220002683300_keaa857-B31","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.thromres.2014.10.013","article-title":"Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant","volume":"135","author":"Pengo","year":"2015","journal-title":"Thromb Res"},{"key":"2021080220002683300_keaa857-B32","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1111\/j.1538-7836.2005.01485.x","article-title":"Lupus anticoagulants and the risk of a first episode of deep venous thrombosis","volume":"3","author":"de Groot","year":"2005","journal-title":"J Thromb Haemost"},{"key":"2021080220002683300_keaa857-B33","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1160\/TH04-12-0839","article-title":"Antibody profiles for the diagnosis of antiphospholipid syndrome","volume":"93","author":"Pengo","year":"2005","journal-title":"Thromb Haemost"},{"key":"2021080220002683300_keaa857-B34","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1111\/jth.12014","article-title":"Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities","volume":"10","author":"Sciascia","year":"2012","journal-title":"J Thromb Haemost"},{"key":"2021080220002683300_keaa857-B35","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/art.33340","article-title":"Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events","volume":"64","author":"Otomo","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2021080220002683300_keaa857-B36","first-page":"675","article-title":"High frequency of abnormal levels of IgA anti-beta2-glycoprotein I antibodies in patients with systemic lupus erythematosus: relationship with antiphospholipid syndrome","volume":"25","author":"Fanopoulos","year":"1998","journal-title":"J Rheumatol"},{"key":"2021080220002683300_keaa857-B37","doi-asserted-by":"crossref","first-page":"e12280","DOI":"10.1371\/journal.pone.0012280","article-title":"IgA anti-\u03b22-glycoprotein I autoantibodies are associated with an increased risk of thromboembolic events in patients with systemic lupus erythematosus","volume":"5","author":"Sweiss","year":"2010","journal-title":"PLoS One"},{"key":"2021080220002683300_keaa857-B38","first-page":"S742","article-title":"IgA anti-\u03b22glycoprotein I antibodies are pathogenetic in a mouse model of APS","volume":"64","author":"Ruiz-Limon","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2021080220002683300_keaa857-B39","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/blood-2007-01-066043","article-title":"Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study","volume":"110","author":"Galli","year":"2007","journal-title":"Blood"},{"key":"2021080220002683300_keaa857-B40","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1161\/STROKEAHA.118.023021","article-title":"Antiphospholipid syndrome with isolated isotype M anticardiolipin and\/or anti-B2GPI antibody is associated with stroke","volume":"49","author":"Urbanski","year":"2018","journal-title":"Stroke"},{"key":"2021080220002683300_keaa857-B41","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1177\/0961203307083316","article-title":"Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus","volume":"16","author":"Martinez-Berriotxoa","year":"2007","journal-title":"Lupus"},{"key":"2021080220002683300_keaa857-B42","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/ard.51.3.353","article-title":"Prospective study of fluctuations of lupus anticoagulant activity and anticardiolipin antibody titre in patients with systemic lupus erythematosus","volume":"51","author":"Out","year":"1992","journal-title":"Ann Rheum Dis"},{"key":"2021080220002683300_keaa857-B43","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/rheumatology\/37.10.1089","article-title":"Anti-beta2-glycoprotein I, anti-prothrombin and anticardiolipin antibodies in a longitudinal study of patients with systemic lupus erythematosus and the antiphospholipid syndrome","volume":"37","author":"Inanc","year":"1998","journal-title":"Br J Rheumatol"},{"key":"2021080220002683300_keaa857-B44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/art.24232","article-title":"Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies","volume":"61","author":"Tektonidou","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2021080220002683300_keaa857-B45","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.1182\/blood-2005-05-2048","article-title":"Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus","volume":"106","author":"Male","year":"2005","journal-title":"Blood"},{"key":"2021080220002683300_keaa857-B46","first-page":"2531","article-title":"Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus","volume":"29","author":"Somers","year":"2002","journal-title":"J Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaa857\/35175469\/keaa857.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/8\/3770\/39543460\/keaa857.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/8\/3770\/39543460\/keaa857.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T16:12:09Z","timestamp":1627920729000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/8\/3770\/6040756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,17]]},"references-count":46,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,12,17]]},"published-print":{"date-parts":[[2021,8,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa857","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2020,12,17]]}}}